Movano Health

What Movano Health does

Movano Health (NASDAQ: MOVE) is a publicly traded medical technology company headquartered in Pleasanton, California, that designs and sells wearable health devices anchored by the Evie Ring, a smart ring purpose-built for women's health monitoring. The company's core technology rests on a proprietary radio frequency (RF)-enabled custom mmWave sensor chip combined with machine learning algorithms, intended to deliver medical-grade biometric data and to underpin non-invasive, cuffless blood pressure and needle-free continuous glucose monitoring. Movano's product portfolio spans the consumer-facing Evie Ring priced at $269 with no subscription, the FDA 510(k)-cleared EvieMED Ring for clinical and pulse oximetry applications (cleared December 2024), the EvieAI generative AI virtual wellness assistant (launched February 2025), and a cuffless blood pressure device in clinical studies targeting future FDA clearance.

The company generates revenue primarily through direct-to-consumer hardware sales via its owned e-commerce storefronts (eviering.com and movanohealth.com), supplemented by HSA/FSA eligibility, and is pursuing enterprise and clinical channels through partnerships with healthcare providers and research institutions (Novant Health, Stanford University, MIT). Movano has raised approximately $117M+ across venture rounds and multiple public offerings between 2020 and 2024, completed its NASDAQ IPO in March 2021, and is led by CEO John Mastrototaro (former Medtronic) and Founder/CTO Michael Leabman. In late 2025, the company announced and closed an all-stock merger with Corvex, an AI cloud computing company, creating a combined entity focused on AI infrastructure and healthcare solutions while Movano continues its medical device operations, and concurrently received a Nasdaq deficiency notification in May 2025 related to delayed quarterly filing.

Name

Movano Health

Legal name

Movano Inc.

Website

https://movanohealth.com

Company type

Public

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Movano Health (NASDAQ: MOVE) is a medical technology company that develops and sells the Evie Ring, a smart ring designed for women's health monitoring, alongside the FDA-cleared EvieMED Ring and EvieAI wellness assistant.

Ownership category

akta.pro rank

Product category

Consumer Health Wearables

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Smart Rings (CRACAIAC)

akta.pro secondary industries

Women’s Health & Fertility Tracking Devices (Ovulation/Temp Sensors, Pelvic Health Devices) (CRACAQAJ), Health Monitoring Wearables (ECG, BP, SpO2, CGM-compatible) (CRACAIAF), Fertility & Ovulation Products (OTC) (CRABAIAK), Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI)

Keywords

• Women's health wearables
• Smart ring devices
• Medical-grade sensors
• Remote health monitoring
• Wearable biometric tracking

Headquarters

HQ city

Pleasanton

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Evie Ring Hardware Sales: Movano Health generates revenue primarily through the sale of Evie Ring hardware. The device is sold at $269 with no subscription fees, representing a one-time hardware purchase model. The company also generates revenue through the EvieAI virtual wellness assistant launched in February 2025.
2. Medical Device Sales (EvieMED Ring): Following FDA clearance in December 2024, Movano Health can generate revenue through the EvieMED Ring for medical/healthcare settings. The company is conducting clinical studies with new cuffless blood pressure devices targeting FDA clearance.
3. Strategic Partnerships and Licensing: Movano Health generates revenue through strategic partnerships with technology companies (e.g., ams OSRAM collaboration) and healthcare providers. The company is developing partnerships for patient data monitoring and blood pressure solutions.
4. HSA/FSA Eligible Products: The Evie Ring is HSA/FSA eligible, allowing consumers to purchase using health savings accounts, expanding the accessible customer base and payment options.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Movano Health designs, manufactures, and sells the Evie Smart Ring, a medical-grade wearable specifically engineered for women's health monitoring that tracks menstrual cycles, body temperature, ovulation, sleep, activity, heart rate, and SpO2. The company is also developing a proprietary Radio Frequency (RF) enabled sensor chip for non-invasive, cuffless blood pressure and glucose monitoring, and offers an FDA-cleared medical-grade variant (EvieMED Ring) for clinical use.

Product overview

Movano Health offers a portfolio of women's health-focused wearable devices centered on the Evie Ring ecosystem. The core consumer offering is the Evie Ring, a smart ring specifically designed for women's health tracking. The EvieMED Ring represents the FDA-cleared medical-grade variant for clinical monitoring. EvieAI provides AI-powered virtual wellness assistance as an integrated feature. The company is also developing a cuffless blood pressure monitoring device leveraging proprietary radio frequency sensor technology. The portfolio spans consumer wellness wearables (Evie Ring) through medical-grade clinical devices (EvieMED Ring) to AI-powered insights (EvieAI), unified by Movano's proprietary sensor platform and insights engine.

Differentiator

Problem solved

Functional benefit

Brands

• Evie Ring: The smart ring designed for women's health that monitors menstrual cycles, body temperature, sleep patterns, and daily activity through medical-grade sensors worn on the finger.
• EvieMED Ring
• EvieAI

Products and services

• Evie Ring Smart ring designed specifically for women's health tracking that monitors menstrual cycles, body temperature (for ovulation prediction), sleep patterns, daily activity, heart rate, heart rate variability, respiration rate, and SpO2 through medical-grade sensors worn on the finger. Sold directly to consumers at $269 with no subscription fees; HSA/FSA eligible.
• EvieMED Ring FDA 510(k) cleared medical-grade smart ring variant with pulse oximetry functionality for clinical and professional healthcare monitoring applications, featuring cryptographically signed firmware for hardware-enforced security.

Quantifiable outcome

• Evie Ring's Pulse Oximeter exceeded FDA accuracy guidelines in Movano Health's second hypoxia trial (March 2024)
• +2 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability4 records

Feature5 records

Partnerships

Seven partnerships are on record, tiered flagship and core.

• MITflagshipStrategic or Co-development Partner · 8 August 2024MIT selected Movano Health for groundbreaking study on Long COVID and Chronic Lyme Disease, validating the company's technology for clinical research applications.
• ams OSRAMcoreTechnology or Integration · 25 January 2024Movano Health and ams OSRAM collaborated to deliver accurate lifestyle monitoring solutions for women. The partnership combines ams OSRAM's sensor technology expertise with Movano Health's women's health platform to enhance the accuracy and capability of the Evie Ring.
• Jay GroupcoreImplementation/ SI/ Consulting Partner · 30 August 2023Jay Group selected as fulfillment provider in preparation for Evie Ring commercial launch. Jay Group handles fulfillment operations and logistics for the consumer product.
• Novant HealthcoreStrategic or Co-development Partner · 13 December 2022Beta program launched with Novant Health to test and advance development of comprehensive health data monitoring for the wearable ring solution in a healthcare setting.
• Stanford UniversitycoreStrategic or Co-development Partner · 15 August 2022Beta program with Stanford University to advance the development of comprehensive health data monitoring for the wearable ring solution, leveraging academic research capabilities.
• American Heart Association Center for Health Technology & InnovationcoreStrategic or Co-development Partner · 3 May 2022Movano joined the Innovators' Network at the American Heart Association Center for Health Technology & Innovation, gaining access to healthcare innovation ecosystem and potential partnerships.
• GLOBALFOUNDRIEScoreTechnology or Integration · 24 September 2020Partnership to advance needle-free continuous glucose monitoring technology. GLOBALFOUNDRIES provides semiconductor manufacturing capabilities for Movano Health's custom RF chips and sensors.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Samsung (Galaxy Ring): Samsung launched the Galaxy Ring in 2024, leveraging massive consumer electronics distribution and ecosystem integration. While not women's-health focused, it competes for the same consumer wearable mindshare and shelf space as Evie.
• Apple (Apple Watch): Apple Watch is the incumbent health wearable with FDA-cleared ECG, SpO2, and growing women's health features. While not a ring, it competes for the same health-tracking wallet share and has vastly greater distribution.
• Dexcom: Dexcom is the continuous glucose monitoring leader. It is a relevant comparable because non-invasive glucose is core to Movano's long-term roadmap; success would compete with Dexcom's installed base.
• Garmin: Garmin's health-focused wearables (Vivosmart, Venu, Index) overlap with Movano's continuous monitoring ambitions. It brings strong brand credibility in continuous biometric tracking.
• Fitbit (Google): Fitbit, owned by Google, offers health-focused wearables including women's health tracking. It competes on consumer health data, ecosystem integration, and brand scale rather than ring form factor.
• Abbott (FreeStyle Libre): Abbott's FreeStyle Libre dominates consumer CGM. Like Dexcom, it represents the incumbent standard that Movano's non-invasive glucose technology would need to displace or complement to justify long-term value.

Direct peers

• Ultrahuman: Ultrahuman's Ring Air is a direct smart ring competitor with a focus on metabolic health (including glucose-tracking ambitions). Comparable DTC hardware-plus-subscription model targeting health-conscious consumers.
• Oura: Oura Ring is the dominant consumer smart ring with established scale and a subscription model. It competes directly with the Evie Ring for health-tracking consumers, but lacks Movano's women's-health specialization and FDA-cleared medical-grade variant.

Emerging players

• Withings: Withings makes connected health devices (scans, watches, sleep) with a clinical-grade positioning similar to EvieMED. Comparable health-vertical brand strategy targeting engaged health consumers.
• RingConn: RingConn offers a subscription-free smart ring competing on price and battery life. It is a relevant emerging direct peer, particularly for budget-conscious health-tracking consumers.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/MovanoInc
• LinkedInlinkedin.com/company/movanohealth
• Facebookfacebook.com/MovanoHealth

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Movano Health